| P/E (FY) | — | Sales (TTM) | $569.6M |
| Earnings (TTM) | -$798.8M | ROE | −8.65% |
| Net Margin | −4.48% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 89.13% |
Mirum Pharmaceuticals is a biopharmaceutical company developing and commercializing therapies for rare and orphan diseases. Its lead product, LIVMARLI (maralixibat), is an orally administered ileal bile acid transporter inhibitor approved for cholestatic pruritus in Alagille syndrome. The company also commercializes Cholbam, a cholic acid capsule for bile acid synthesis disorders and peroxisomal disorders, and Chenodal.
| Market Cap | $6.84B | Trading Days | 1761 |
| 52W High | 130.00 |
| 52W Low | 50.25 |
| % Off High | −13.67% |
| YTD | 42.08% | 1Y | 117.96% |
| 3Y | 335.17% | 5Y | 704.52% |
| Since incept. (ann.) | 35.59% |
Reportable 100%
| Ann. Volatility (1Y) | 46.36% | Ann. Volatility (3Y) | 47.62% |
| Sharpe (1Y) | 1.96 | Sharpe (3Y) | 1.28 |
| Max Drawdown (1Y) | −20.55% | Max Drawdown (3Y) | −32.52% |
| Beta (3Y, vs SPY) | 0.87 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | $6.66B | 9.7 |
| COGT | Cogent Biosciences, Inc. | $6.48B | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.40B | — |
| XENE | Xenon Pharmaceuticals Inc. | $6.28B | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.27B | 105.9 |
| LQDA | Liquidia Corp | $7.72B | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.98B | 85.3 |
| LGND | LIGAND PHARMACEUTICALS INC | $5.94B | 48.3 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| ERAS | Erasca, Inc. | $5.65B | — |
| TGTX | TG THERAPEUTICS, INC. | $8.40B | 19.8 |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $5.55B | — |
